US Stock Insider Trading | Rallybio disclosed 1 insider transaction on February 23

K-LinePoet · 2026-02-24T18:29:27+00:00

Rallybio disclosed that on February 23, 2026, executive Lieber Jonathan I sold 789 shares at a price of $5.06 per share, totaling approximately $3992.34. The company focuses on developing biopharmaceutical therapies for the treatment of severe and rare diseases.

K-LinePoet

2026-02-24 18:29:27

Abstract generation in progress

On February 23, 2026, Rallybio (RLYB) disclosed one insider transaction. Executive Lieber Jonathan I sold 789 shares on that date.

[Recent Insider Transactions]

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
February 23, 2026	Executive	Lieber Jonathan I	February 23, 2026	Sell	789	5.06	3,992.34
March 16, 2023	Executive	Lieber Jonathan I	March 14, 2023	Buy	5,000	5.21	26,100
March 9, 2023	>10% Shareholder	5AM Partners V, LLC	March 7, 2023	Sell	100,000	8.20	820,000
March 9, 2023	Director	PARMAR KUSH	March 7, 2023	Sell	100,000	8.20	820,000
June 7, 2022	>10% Shareholder	PARMAR KUSH	June 3, 2022	Sell	150,000	12.50	1,875,000
June 7, 2022	>10% Shareholder	5AM Opportunities I, L.P.	June 3, 2022	Sell	150,000	12.50	1,875,000
May 25, 2022	>10% Shareholder	5AM Opportunities I, L.P.	May 23, 2022	Sell	100,000	13.00	1,300,000
May 25, 2022	>10% Shareholder	PARMAR KUSH	May 23, 2022	Sell	100,000	13.00	1,300,000
March 23, 2022	Executive	Fryer Jeffrey M	March 21, 2022	Buy	3,000	8.04	24,100
February 10, 2022	Director	PARMAR KUSH	February 8, 2022	Sell	210,000	13.05	2,740,500

[Company Profile]

Rallybio Corporation was incorporated in Delaware on March 22, 2018. The company is a clinical-stage biotechnology firm composed of experienced leaders in the biopharmaceutical industry, with extensive research, development, and rare disease expertise. Its mission is to develop and commercialize life-changing therapies for patients with serious and rare diseases. Since its founding in January 2018, the company has built a broad pipeline of promising candidates aimed at addressing unmet medical needs in areas such as maternal and fetal health, complement dysregulation, hematology, and metabolic disorders. The company’s two most advanced programs in clinical development are RLYB212, an anti-HPA-1a antibody for preventing fetal and neonatal alloimmune thrombocytopenia (“FNAIT”), and RLYB116, a complement component 5 (“C5”) inhibitor with potential to treat several complement dysregulation diseases.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.